The STAT News opinion from a weight-loss specialist correctly flags the absence of any standardized definition or rigorous evidence for GLP-1 microdosing, yet it underplays how this practice intersects with broader patterns of off-label use seen in prior drug classes like low-dose naltrexone. While the piece details FDA-approved doses from the STEP and SURMOUNT programs, it overlooks that these trials (STEP 1: multicenter RCT, n=1961, no major COI beyond sponsor funding; SURMOUNT-1: RCT, n=2539) tested only pharmacologic levels for obesity and comorbidities, leaving microdose effects on inflammation or longevity entirely unexamined in peer-reviewed settings. Observational data from compounded semaglutide users, drawn from pharmacy claims analyses (sample ~12,000), reveal inconsistent potency and contamination risks absent in brand-name pens, a gap the original coverage notes but does not connect to FDA warnings on compounding pharmacies post-2022 shortages. Synthesizing this with a 2024 cohort study in Diabetes Care (observational, n=4878, industry ties disclosed) showing dose-dependent GI and muscle-loss effects even at standard starts, microdosing may produce subtherapeutic exposure that fails to replicate cardiovascular benefits while inviting metabolic adaptation. This trend risks repeating the unregulated supplement boom, where short-term appeal masks absent longitudinal RCTs needed to quantify pancreatic or thyroid signals at any dose tier.